Vimarsana
Biggest News Aggregation in the World

Lung Fact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lung Fact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lung Fact Today - Breaking & Trending Today

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial - Vimarsana News

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

Published: June 2, 2024

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 2, 2024--

Source: joplinglobe.com
Related Topics:
United StatesUnited KingdomChelsea TresslerDaiichi SankyoBrendan McevoyAmerican Society Of Clinical OncologyWorld Health OrganizationLungevity FoundationLung Ambition AllianceInternational Agency For Research On CancerArchives Pathology LabSingle Institution StudyPlenary SessionClinical OncologyAnnual MeetingNew England JournalPrescription InformationPatient InformationSouth AmericaRare DiseasesInternational AgencyLung FactAccessed MayCancer BiomarkersPresent Status
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial - Vimarsana News

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Published: April 5, 2024

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial ...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomNoord HollandSuresh SenanSusan GalbraithDaiichi SankyoLungevity FoundationWorld Health OrganizationInternational Agency For Research On CancerAmerican Cancer SocietyNational Cancer InstituteAmsterdam University Medical CenterLung Ambition AllianceExecutive Vice PresidentFatal Immune Mediated AdverseMediated NephritisStevens Johnson SyndromeFull Prescribing InformationMedication GuideSouth AmericaRare DiseasesCell LungAccessed AprilRelapsed Small Cell Lung CancerSmall Cell Lung Cancer
AstraZeneca : Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial - Form 6-K -April 05, 2024 at 06:26 am EDT - Vimarsana News

AstraZeneca : Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial - Form 6-K -April 05, 2024 at 06:26 am EDT

Published: April 5, 2024

A4121j FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesNoord HollandSusan GalbraithAstrazeneca ImfinziAdrian KempDaiichi SankyoSuresh SenanLung Ambition AllianceCompany SecretaryCommission File NumberInternational Agency For Research On CancerNational Cancer InstituteSecurities ExchangeWorld Health OrganizationLungevity FoundationAmsterdam University Medical CenterAmerican Cancer SocietyInvestor Relations TeamForeign IssuerSecurities Exchange ActFile NumberCrick AvenueRegulationst RuleExecutive Vice President
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - Vimarsana News

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Published: February 19, 2024

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting ...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomSuresh RamalingamSusan GalbraithCerner CancermpactDaiichi SankyoInternational Agency For Research On CancerAmerican Cancer SocietyLung Ambition AllianceWinship Cancer Institute Of Emory UniversityLungevity FoundationSingle Institution StudyWorld Health OrganisationExecutive DirectorWinship Cancer InstituteEmory UniversityExecutive Vice PresidentPrescription InformationPatient InformationSouth AmericaRare DiseasesInternational AgencyLung FactAccessed FebruaryWhat Is Lung
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial - Vimarsana News

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Published: October 23, 2023

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--

Source: valdostadailytimes.com
Related Topics:
United StatesSusan GalbraithAaron LisbergDaiichi SankyoJennifer BrennanDatopotamab DeruxtecanAnn OncKoji OgiwaraKen TakeshitaAnticancer ResearchDaiichi Sankyo Co LtdWorld Health OrganizationSapporo Medical UniversityDaiichi Sankyo IncEuropean Society For Medical OncologyNational Cancer InstituteInternational Agency For Research On CancerAmerican Cancer SocietyMerck Co IncPresidential SymposiumEuropean SocietyMedical OncologyMedian DorThoracic Medical OncologyGlobal Head